Skip to main content
. 2021 Nov 18;12:6714. doi: 10.1038/s41467-021-27051-8

Table 2.

Pharmacokinetic and pharmacodynamic parameters.

Parameter Value (%RSE, 95% CI) Interindividual variability, % (%RSE, 95% CI)
Pharmacokinetic parameters
N (subjects/PK observations) 280/4573
Clearance (L/d)a 867 (10.2%, 727–1064) 27.1 (15.1%, 22.0–31.0)
 ϴ Post menstrual age EC50a (weeks) 96 (15.4%, 73–130)
Volume of central compartment (L) 592 (10.1%, 484–717) 32.8 (56.3%, 11.8–48.5)
Intercompartmental clearance 1 (L/d) 511 (12.4%, 401–645)
Volume of peripheral compartment 1 (L) 7240 (8.2%, 6210–8440)
Intercompartmental clearance 2 (L/d) 671 (16.8%, 461–934)
Volume of peripheral compartment 2 (L) 1060 (18.2%, 731–1510)
Absorption transit time (d)b 0.045 (9.1%, 0.034–0.048) 43.2 (42.2%, 22.4–60.1)
 ϴ Capillary to venous conversionc 0.922
Proportional error 44.6% (1.7%, 43.0%–46.0%)
Relative bioavailability (F)b 1
 ϴ Weight for age z-scored 0.113 (18.9%, 0.061–0.137)
 ϴ Self-administered DPd 0.397 (7.8%, 0.344–0.465)
 ϴ Between occasion variability 66.9% (5.9%, 62.3%–71.3%)
Pharmacodynamic parameters
N (subjects/observations) 280/326
Baseline hazard/1000 (per day)e 0.402 (17.2%, 0.268–0.536) 69.6 (66.1, 43.3–146)
Season adjustment
 ϴ Transmission period 2015 1.29 (33.9%, 0.65–2.40)
 ϴ Transmission period 2016 5.20 (16.1%, 3.92–7.09)
 ϴ Transmission  period 2017 7.83 (16.7%, 5.75–10.96)
 ϴ PPQ EC50 (ng/mL) 6.00 (14.4%, 4.25–7.58)
 ϴ PPQ γ 3.13 (24.3%, 1.96–4.89)

Confidence intervals obtained by bootstrap (n = 1000).

aCL = ϴCL *Weight8.6kg0.75*PostmenstrualageθPostmenstrualageEC50+Postmenstrualage.

bPre-specified absorption compartments.

cln([PPQ]capillary) = ϴ slope*ln([PPQ]venous).

dF = 1* ϴSelf-administered DP *(1 + ϴWAZ*(WAZ−(−0.5)))*eϴ Between occasion variability, WAZ weight for age z-score.

eSurvival function: ϴBaseline/1000* ϴTransmission  period*[PPQ]γθEC50γ+[PPQ]γ.